Antiplatelet agents for preventing pre-eclampsia and its complications

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Maternal-Fetal Medicine

Background:

• Pre-eclampsia is linked to imbalanced prostacyclin and thromboxane production.
• This imbalance suggests antiplatelet agents, like aspirin, may prevent pre-eclampsia.

Purpose of the Study:

• To evaluate the effectiveness and safety of antiplatelet agents for preventing pre-eclampsia in at-risk women.

Main Methods:

• Systematic review and meta-analysis of 77 randomized trials involving 40,249 women.
• Individual participant data (IPD) and aggregate data (AD) were used for analysis.
• Outcomes assessed included pre-eclampsia, preterm birth, fetal/neonatal death, and maternal/infant adverse events.

Main Results:

• Antiplatelet agents reduced proteinuric pre-eclampsia by 18% (NNTB 61) and preterm birth by 9% (NNTB 61).
• Significant reductions were observed in fetal/neonatal deaths (14%, NNTB 197) and small-for-gestational age infants (16%, NNTB 146).
• A slight increase in postpartum hemorrhage (>500 mL) was noted (moderate-quality evidence).

Conclusions:

• Low-dose aspirin demonstrates significant benefits in reducing pre-eclampsia and related adverse outcomes.
• The overall safety profile is favorable, with a slight increase in postpartum hemorrhage as a potential risk.
• Further research is needed to optimize treatment timing and identify women most likely to benefit.